A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

A new bombshell has been dropped in the scandal-plagued world of Alzheimer’s disease drug development. | Between the two ...

England’s drug-cost regulator rejected Eli Lilly’s Alzheimer’s drug for use in the country’s public health system, marking ...

Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.

'Mad Money' host Jim Cramer weighs in on stock including: Viper Energy, Nextracker, Trump Media, Eli Lilly, and Dutch Bros.

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval ...

Britain's National Health Service (NHS) will block Eli Lilly's Alzheimer's drug donanemab on Wednesday, deeming it too ...

Lots of money is pouring into two critical races for Washington's legislature this year — and some big name companies are ...

The company is suing some online vendors and medical spas for selling copycats of a weight loss and diabetes drug.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.